Adverse Reactions and Gastrointestinal Tract by A. Lorenzo Hernández et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
25 
Adverse Reactions and  
Gastrointestinal Tract 
A. Lorenzo Hernández1, E. Ramirez.1  
and Jf. Sánchez Muñoz-Torrero2 
1University Autonoma of Madrid 
2University of Extremadura 
Spain 
1. Introduction 
Adverse drug reactions are common and there is an increasing interest in recognizing them. 
There are several studies that try to identify epidemiology, true incidence in hospitalized 
and not hospitalized patients and the main concerns about their causes and possible 
solutions. Gastrointestinal tract, mainly haemorrhages and peptic disease are the most 
common site of adverse drug reactions; that´s the reason why we should recognize this 
problem and how to manage. Also we try to review the most common drugs affecting 
gastrointestinal tract. Less common and, usually less severe, liver disease and pancreatitis 
can be produced by adverse drug reactions. In this chapter we review theses aspects of 
adverse drug events, particularly, those related to drugs affecting gastrointestinal tract. 
2. Definition of adverse drug reactions 
An adverse drug event is an unwanted and unintended medical event related to the use of 
medications. An adverse drug event is considered an adverse drug reaction (ADR) when 
there is a causal link between the event and use of the drug. An adverse drug reaction is 
considered serious when the patients outcome is one of the following: death, life-
threatening, hospitalization (initial or prolonged), disability –significant, persistent or 
permanent change, impairment, damage or disruption in the patient’s body 
function/structure or physical activities or quality of life, congenital anomaly or require 
intervention to prevent permanent impairment or damage [Supplementary information in 
Appendix 1].  
Causality assessment is necessary to determine the likehood that a drug caused a suspected 
ADR. There are a number of different methods used to judge causation, the first attempts 
were proposed by Karch and Lasagna (1977), Lecenthal et al. (1979) and Naranjo et a.l 
(1981). Most of these approaches to assigning causality are based on the following clinical 
features: temporal relationship between drug exposure and the onset of adverse drug event, 
characteristic symptoms and laboratory abnormalities and/or histology, and challenge-
dechallenge-rechallenge (improvement after stopping the suspected drug and reappearance 
after starting the agent in question). 
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ADRs can be considered “on-target” effects, if they are result of exaggerated pharmacology 
that may be managed by dose reduction or other therapeutic modifications, i.e. 
hypoglycemia associated with antidiabetic agents. “Off-target” toxicities are frequently 
more problematic because they may not be predicted from pharmacology and toxicology 
studies, and they may occur only after prolonged exposure, i.e. hypersensibility reactions 
associated to antiepileptics. Unexpected ADRs that first appear after marketing 
authorization of the medication continue trouble clinicians, regulators, and drug sponsors. 
The most notably cause is the use by large number of patients, providing sufficient statistical 
power to detect rare events. Other factors include use in special populations, drug inte 
ractions, renal and hepatic insufficiency, long duration of use and drug withdrawal.  
3. Epidemiology of adverse drug reactions 
Adverse drug reactions (ADRs) are considered to be among the leading causes of morbidity 
and mortality. Around 5-25% of hospitals admissions are estimated to be due to ADRs and 
about 6-15% of hospitalized patients experience serious ADRs (SADRs) causing significant 
prolongation of hospital stay and projected that adverse drug events are the fourth to sixth 
leading cause of death in the United States. Most studies are focused on rates of serious and 
fatal events in hospitalized patients, probably because tracking of ADRs is more established 
in the inpatients setting. An English study (Kane-Gill, 2010) found an increase in 
hospitalizations caused by ADR in about 76.8% in ten years. A recent study of 
administrative health-care data found an annual ADR prevalence rate of 0.5% among 
ambulatory-care patients; however, the authors acknowledge this is probably an 
underestimate of true ADR rates. Ambulatory-care patients experiencing an ADR were 
younger on average than hospitalized patients.  
Risk factors of suffering adverse drug events are: women, elderly and polipharmacy mainly. 
Women were more likely than men to have ADRs in both outpatients and inpatients 
settings. In the study from Zopf (2008), the OR of women from suffering ADR was 1.562; 
(95% CI 0.785, 2.013). Other risk factors implicated in adverse drug reactions are elderly, 
drug-drug interactions, polipharmacy and renal insufficiency. In the study of Sanchez 
Muñoz (2011), also drug-drug interactions were as important as age and renal insufficiency 
in producing adverse drug reactions. 
Patients affected by adverse dug events are admitted in internal medicine department and 
geriatrics quite often, but patients hospitalized in Intensive care units and pediatrics also 
suffer from these problems.  
4. Severity of adverse drug reactions – Fatal adverse drug reaction 
It has been estimated than fatal ADRs are expected in approximately 0.32% of hospitalized 
patients, and complications from drug therapy are the most common adverse event in 
hospitalized patients. If true, then ADRs are the 4th leading cause of death—ahead of 
pulmonary disease, diabetes, AIDS, pneumonia, accidents, and automobile deaths. 
However, some studies show greater severity prevalence and fatality rate. In the hospital 
setting the study from Kaurr, (Kaurr,2011) observed grade severe of adverse reaction in 
13.4% patients. In the study from Sánchez Muñoz-Torrero (2010) the reactions were severe 
in 17% and fatal in 1.6% of hospitalized patients.  
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These statistics do not include the number of ADRs that occur in ambulatory settings. The 
exact number of ADRs is not certain and is limited by methodological considerations. 
However, whatever the true number is, ADRs represent a significant public health problem. 
In a Sweden study there were reviewed the death reports in one year in relation with 
adverse drugs reactions. They found 3.1% of deaths associated with fatal adverse drug 
events, mostly haemorraghes. 89% of patients died at hospital meanwhile only 35% of 
patients dead at hospital with no relation with drug events. 
So most of studies trying to establish epidemiology and cost of adverse drug reactions 
demonstrate that these events are harmful and we have to make great efforts to diminish the 
incidence and morbidity.  
5. Cost of adverse drug reactions 
In western countries, drug-related illnesses account 5% to 10% of inhospital costs, and being 
associated with a substantial increase in morbidity and mortality. In addition to their impact 
on human health, ADRs also have significant impact on healthcare costs. These costs are 
essentially hospital costs, in particular arising from an increase in length of stay caused by an 
ADR. Although has been estimated that the occurrence of an ADR during hospitalization or 
leading to hospitalization is responsible in U.S.A. (data from 1997) for a cost of approximately 
2800 Euros in an additional length of stay of 2.2 days, several studies have also pointed out 
that the structure of ADR cost is heterogeneous, a factor which must be taken into account 
when developing preventive strategies. Although data of costs were not calculated, Sanchez 
Muñoz-Torrero et al (2010) study found an increase in hospital staying in almost 9 days (18±17 
days vs 9.6±5.8, p<0.001), which accounts for more direct and indirect costs of the 
hospitalization. Also another Spanish (Carrasco Garrido et al, 2010) study found an increase in 
19% of hospital costs associated with the appearance of adverse drug events. 
6. Potential causes implicated in adverse drug reactions 
Older patients are particularly vulnerable to drug-related illness because they are usually on 
multiple drug regimens, which expose them to the risk of drug interactions (Mallet et al, 
2007), and because age is associated with changes in pharmacokinetics and 
pharmacodinamics (Aronson, 2007).  
Onder et al. (2010) developed and validated a risk stratification model (The GerontoNet 
ADR Risk Score) to identify patients 65 years or older who are at risk for an ADR during 
hospitalization. They used data from the Italian Group of Pharmacoepidemiology in the 
Elderly to develop an ADR risk score. The ADR risk score was then validated in a sample of 
older adults who were admitted to 4 university hospitals in Europe. The number of drugs 
and history of an ADR were the strongest predictors of ADRs, followed by heart failure, 
liver disease, presence of 4 or more conditions, and renal failure (Table 1).  
Recently Sánchez Muñoz-Torrero et al found that renal function and drug–drug interactions 
were statistically significant associated with the appearance of ADR. Also duration of 
hospitalization was associated but it wasn’t possible to establish that if duration of 
hospitalization was the cause or the consequence of ADR. Recently Hamilton et al (2011) 
reviewed the adverse drug reactions in older people with potentially inappropriate 
prescriptions. 
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Variable  OR (95% CI) Points 
4 Comorbid conditions 1.31 (1.04-1.64) 1 
Heart failure 1.79 (1.39-2.30) 1 
Liver disease 1.36 (10.6-1.74) 1 
No. of drugs   
  5 1 [Reference] 0 
 5-7 1.90 (1.35-2.68) 1 
 8 4.07 (2.93-5.65) 4 
Previous ADR 2.41 (1.79-3.23) 2 
Renal failure 1.21 (0.96-1.51= 1 
Abbreviations: ADR, adverse drug reactions; CI, confidence interval; OR, odd ratio.  
Table 1. Variables included in the Score (adapted from Onder et al) 
7. Main drugs implicated in reactions 
Drug classes most frequently associated with ADRs in both inpatients and outpatient 
populations are non steroidal anti-inflamatory drugs (NSAIDs), diuretic, anticoagulants, 
antiobiotics and antineoplastic agents.  
Antibiotic and vaccination reactions are more frequent in the 0 –to-9 year age group.  
In adults and elderly people, there a great variety of drugs causing adverse drug reactions. 
However, it depends the type of hospitalization, the deparment, etc, the type of adverse 
reactions and drugs implicated are quite different. Pimohamed et al. (2004) found that 
aspirin was the casual agent in 18% of cases of all admission for ADRs, while other NSAIDs 
and diuretics were implicates in 12% and 27% respectively. The most common ADRs of 
NSAIDs were GI bleeding, peptic ulcerations, haemorrhagic cerebrovascular accident, renal 
impairment, wheezing and rash. Grenouillet-Delacre et al. (2007) found that psychotropic 
drugs, immunosuppressive drugs, anticoagulants and antibiotics were more than 50% of 
life-threatening adverse drug reactions at admission to medical intensive care. In Spain, 
antibiotic and anticoagulants are the drugs more frequently implicated in ADRs appeared 
during hospitalization but in another epidemiologic study (Carrasco Garrido, 2010) found 
that main drugs implicated in admission into the hospital were antineoplastics and 
immunosuppressive therapy. However there are very few studies that show antineoplastics 
and immunosuppressive therapies as the cause of adverse drug reactions although they are 
being increasingly used and promote the appearance of infections, medullar aplasia, etc. 
Also cardiovascular drugs, mainly diuretics and hypotensors drugs account for some 
common ADRs. 
8. Drugs reactions affecting gastrointestinal tract 
ADR that cause damage in gastrointestinal tract usually produce GI bleeding/peptic 
ulcerations, diarrhea (mainly associated to antibiotics), pancreatitis and liver toxicity. About 
40% of ADR affect gastrointestinal and liver in hospitalized patients. As said before, 
gastrointestinal bleeding is the most frequent ADRs causing hospitalization or produced 
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during hospitalization. In this issue, we try to review the ADRs affecting gastrointestinal 
tract. 
8.1 GI bleeding 
Mainly non steroidal anti-inflammatory drugs and antiplatelet/anticoagulants are implicated 
in gastrointestinal bleeding. The most frequent lesion is gastric erosions (about 40.2%), 
combination of gastric ulcer and gastric erosions (16.1%), gastric ulcer (15.0%), duodenal ulcer 
(13.8%), normal (13.8%) and duodenal erosions (1.1%). In a recent study 26% of patients 
admitted because of gastrointestinal bleeding had antiplatelet or anticoagulants as the cause 
of bleeding. The distribution of lesions was quite similar to the study from Devy, being 
gastric ulcer the most common lesion involved in the bleeding. Inhibition of cyclooxygenase, 
leading to inhibition of gastric prostaglandin synthesis, and impaired GI defense mechanisms 
represent additional mechanisms of drug-induced GI bleeding. In the particular setting of 
Intensive Care Units (ICUs) the most frequent lesion found in patients is the stress-related 
mucosal bleeding, in which another causes apart from drugs are implicated. In the study 
from Wikman-Jorgensen (2011) mortality of upper gastrointestinal bleeding was 3,5%, all in 
patients with great comorbidity which limited treatment of bleeding. 
Drugs most frequently causing bleeding were aspirin in 36%, acenocumarol in 27%, 
clopidogrel in 18%. Combination of aspirin and clopidogrel are responsible of 6% of upper 
gastrointestinal bleeding. Aspirin is the drug more frequently implicated but it may chance 
in the future because of the increasing use of doble antiplatelet treatments and new 
anticoagulants (Rivaroxaban, Apixaban and Dabigatran). It is possible than in the near 
future we begin to see hemorrhages with dabigatran because of the recent approval in USA 
for the use of treatment in atrial fibrillation, including patients with low risk of 
thromboembolism. The risk of bleeding is bigger with Rivaroxaban as shown in the 
prophylaxis studies, but the approval for AF is pending. 
Also lower gastrointestinal bleeding is increasing because of use of AINES mainly. New 
techniques for diagnosing lesions in small and large intestine are proving this increase in 
lower gastrointestinal bleeding. AINES can cause diverticulum perforation, mucosal 
inflammation, ulceration, causing bleeding in the intestine. Use of aspirin, clopidogrel or 
anticoagulants and the lower intestinal bleeding is an issue that has to be studied because of 
its frequency, use and potential harmful in small and large intestine. There´s little 
information about its presentation and management.  
8.2 Diarrhea 
Diarrhoea may be defined by frequency or grams of loose grames per day: 3–5 times per day 
and/or loose stools 200– 300 grams/day (250 mL/day).  
It´s estimated that diarrhoea accounts for the 7% of ADRs. There are lot of drugs producing 
diarrhea as a secondary effect: metformin, some chemotherapies, antibiotics, mainly 
clavulanic, clindamicin, immunosuppressant… Most of them cause diarrhea only while 
taking, or only at the beginning of prescription, but some are associated with chronic 
diarrhoea as metformin. However, the possibility of a drug causing a severe diarrhea is less 
common except in the case of antibiotics, hipomotility drugs, steroids, proton pump 
inhibitors because of the possibility of Clostridium difficile diarrhea.  
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Mechanisms of drugs producing diarrhoea are multiple: osmotic, secretory, motor, 
exudative, malabsorptive, infectious/inflammatory, and others. Examples of osmotic 
diarrhoea are enteral nutrition feeding, magnesium salts, etc. Examples of secretory 
diarrhoea (increase in intestinal ion secretion or diminution in intestinal ion absorption) are 
digoxin, quinidine, propafenone and theophiline. Examples or rapid intestinal transit are 
procinetic and macrolids. Exudative diarrhoea (changes in permeability and integrity of 
intestinal mucosa) are NSAIDs and antineoplastic. Drug-related malabsorption of fats, 
carbohydrates, and/or bile can also lead to diarrhea. Examples include octreotide (at high 
doses), highly active antiretroviral therapy, tetracycline, NSAIDs, and antineoplastic agents. 
Drug-induced infectious/inflammatory diarrhea includes microbial proliferation, 
pseudomembranous colitis, and histologic colitis. The risk of antibiotic associated diarrhea 
is higher with broad-spectrum agents (particularly those with antianaerobic activity and 
activity against Enterobacteriaceae), agents with high luminal concentrations (although 
oral/enteral administration is not necessarily a risk), longer duration of therapy, and use of 
multiple antibiotics. 
8.3 Constipation and hypomotility 
Anticholinergic drugs are responsible of constipation as well as other adverse reactions in 
patients, particularly elderly patients. Also opioids prescribed for cancer patients, chronic 
pain, etc are responsible of constipation which can produce paralitic ileum. In the setting of 
ICU patients hipomotility and constipation appears in 50-80 % of patients, particularly those 
with mechanically ventilated.  
8.3.1 Hypomotility 
Hypomotility is produced mainly abnormalities in propulsive motility, disturbances in 
esophageal and gastric motility, reduction in lower esophageal sphincter pressure. 
Exogenous cathecolamines can reduce antral contractions and small bowel peristalsis and 
alter motility patterns. Opioids inhibit neurotransmitters release and altering water and 
electrolyte absorption.  
8.3.2 Constipation 
Constipation is produced by changes in neuronal or motor function in the intestine. The 
most common cause is opioids. They inhibit the release of acetylcholine from the myenteric 
plexus and promote in the opioid receptors in the intestine a decreased motility and increase 
in intestinal fluid absorption. Other drugs implicated in constipation are antihistamines, 
calcium channel blockers, diuretics, tricyclic antidepressants.  
8.4 Pancreatitis 
Drug induced pancreatitis accounts for 0.1-2% of pancreatitis. Between 1968 and 1993 a total 
of 525 different drugs from many different substance classes have been reported to the 
WHO because they were suspected to induce pancreatitis as an unwanted side effect, The 
three drugs that are responsible of more cases of pancreatitis are mesalazine, azathioprine 
and simvastatine. Previously recognized patients with more risk of pancreatitis are pediatric 
and elderly patients, women, advanced HIV disease and inflammatory bowel disease. The 
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interesant review from Balani (2008) showed a table with drugs commonly implicated in 
pancreatitis: ACE inhibitors, ARA-2, loop diuretics and thiazides, statins, bezafibrate, some 
antibiotics, pentamidine, azathioprine, mercaptopurine, aminosalicylates, anticonvulsivants 
and antipsychotics, estrogens, carbimazole, some antineoplastics, codeine, sulindac.  
In critically ill patients there’s also a review of drugs implicated in pancreatitis (Lat, 2010):  
8.4.1 Drugs with a likely association 
Drugs with a likely association: Asparaginase, azathioprine, cimetidine, corticosteriopids, 
corticotrophin, cytarabin, dapsone, didanosine, enalapril, estrogens, furosemide, isonizid, 
mercaptopurine, mesalamine, methyldope, metronidazole, omeprazol, opiates, 
pentamidine, pravastatin, salycilates, simvastatin, sulfasalizine, 
sulfamethoxazole/trimethoprim, sulindac, tetracycline, valproic acid.  
8.4.2 Drugs with a potential or questionable association 
Drugs with a potential or questionable association: acetaminophen, amiodarone, 
ampicilin, benzapril, carbamazepine, captopril, ceftriaxone, clarithromycin, cyclosporine, 
diphenoxylate, cisplatinerythromycin, fluvastatin, gemfibrozil, interferon, ribavirin, 
ketoprofen, lisinopril, ketoprofen, lisinopril, lovastatin, metformin, naproxen, thiazides, 
octerotide, penicillin, procainamide, propofol, propoxyphene, ramipril, ranitidine, rifampin. 
8.5 Drug-Induced Liver Injury (DILI) 
Hepatotoxicity and drug-induced liver injury (DILI) are terms used interchangeably. DILI 
can be defined as a liver injury induced by a drug or herbal medicines leading to liver test 
abnormalities or liver dysfunction with reasonable exclusion of other competing etiologies. 
Most cases of DILI are due to idiosyncratic or unexpected reactions. In contrast to 
paracetamol-induced hepatotoxicity, which occurs with dose-dependent overdose of the 
drug. Idiosyncratic drug reactions have been traditionally considered dose independent. 
However, drugs with well-documented idiosyncratic DILI have been shown to have a dose-
dependent component. Idiosyncratic DILI, excluding injury caused by acetaminophen 
overdose, accounts for 7–15% of the cases of acute liver failure in Europe and the United 
States and is the most frequent reason for the withdrawal of an approved drug from the 
market. Estimates of the rate of incidence of DILI leading to hospital referral vary from 2.4 
per 100,000 person-years (in a retrospective population-based study of 1.64 million UK 
subjects) to 13.9 per 100,000 inhabitants (in a prospective analysis in France). 
Complementary or alternative medicines are used by at least 20% of individuals in Western, 
Eastern, and African cultures, and reports of DILI have increased. Given its rarity, DILI may 
not be identified during clinical trials and may come to light only after the culprit drug has 
obtained market approval and large numbers of patients have been exposed. In addition, in 
preregistration clinical trials, mild asymptomatic liver injuries, often characterized by 
asymptomatic elevations in liver enzymes, are commonly seen. However, drugs capable of 
inducing severe DILI as well as drugs that have a low potential for causing severe injury 
(e.g., aspirin and heparin) can generate similar patterns of liver injury. It is therefore 
necessary to develop an approach that can distinguish drugs that are likely to cause severe 
DILI from drugs that are unlikely to do so.  
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RUCAM algorithm (Roussel Uclaf Causality Assessment Method) was the first algorithm 
developed specifically for DILI. After the meeting sponsored by the CIOMS (Paris, 1989), with 
the support of Russel Uclaf pharmaceutical company, the terminology and diagnosis criteria 
for causality assessment was proposed. The algorithm was validated using external cases with 
positive rechallenge (49 cases) and 28 controls (patients with acute liver damage not related to 
drugs) with available information before occurrence of re-exposure, with results of high 
sensitivity (86%), specificity (89%), positive predictive value (93%) and negative predictive 
value (78%) [Algorithm RUCAM are showed in Table 1 and 2 of Appendix 2]. 
International DILI Expert Working Group of clinicians and scientists reviewed current DILI 
terminology and diagnostic criteria so as to develop more uniform criteria that could be 
define and characterize the spectrum of clinician syndromes that constitute DILI. In 
Appendix 2 of supplementary information you will find threshold criteria for definition of a 
case as being DILI (Box 1), the pattern of liver injury (Box 2), severity (Box 3), causality 
assessment (Box 4), and chronicity (Box 5). Consensus was also reached on approaches to 
characterizing DILI in the setting of chronic liver diseases (Box 6), including autoimmune 
hepatitis (Box 7). 
A very large number of different drugs have been associated with liver injury. There is a 
clear difference in the documentation or the evidence for hepatotoxicity associated with 
these drugs. Isoniazid, phenytoin, disulfiram, amoxicillin/clavulanate, halothane and 
chlopromazine are drugs with well characterized hepatotoxicity. More recently antibiotics 
(amoxicillin/clavunalate, erytromicin, flucloxacillin, trimethoprim-sulpha, nitrofurantoin, 
isoniazid and rifampicin), analgesics and NSAIDs (diclofenac, dextropropoxyphene, 
paracetamol, ibuprofen) probably the most common type of drugs associated with DILI. In 
hospitalized patients, antineoplasic agents seem to commonly lead to DILI and are probably 
underreported. In a Spanish pharmacovigilance prospective program based on laboratory 
signals at hospital all patients with liver test abnormalities ( x 3 upper limits of normal) were 
evaluated being antibiotics (19.5%), hormonal contraceptives (14.6%) and anticancer agents 
(10%) were the most frequent drug-groups associated to liver injury. In out-patients, the 
single most common drug implicated in ine series was diclofenac. Among patients with 
acute liver failure resulting from drugs in the US who underwent liver transplantation, 
paracetamol (acetaminophen) was the most common causative drug, followed by isoniazid, 
propylthiouracil, phenytoin and valproate.. Herbal and dietary supplements are implicated 
in approximately 11% of patients who developed acute serious liver disease of unknown 
cause in Spain.  
The expectrum of DILI is varied, acute liver injury with or without jaundice, chronic 
hepatitis, although rare, liver cirrhosis has been reported to occur with long-standing drug 
treatment suspected to have caused DILI, and approximately 25-30% of DILI present with 
symptom of immunoallergic drug reactions. Table 2 showed the most common types of liver 
injury that have been identified with drugs. 
9. Drugs for gastrointestinal diseases and their implication in adverse 
reactions 
Most of adverse reactions with drugs used for treating gastrointestinal diseases are proton 
pump inhibitors. New antiTNF drugs, steroids and immunosuppressant in general used for  
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Type Drugs 
Acute liver injury Isoniazid, disulfiram, paracetamol 
Chronic hepatitis Phenytoin, isoniazid 
Autoimmune hepatitis Minocycline, nitrofurantoin 
Granulomatous hepatitis Carbamazepine, quinidine 
Steatohepatitis Amiodarone, valproate 
Cholestatic hepatitis Flucloxacillin, amoxicillin ⁄ clavulanate 
Bland cholestasis Estrogens, nimesulide  
Ductopenia Amoxicillin, Trimethoprim-sulpha 
Fibrosis Methotrexate  
Nodular regenerative hyperplasia Azathioprine, 6-thioguanine 
Table 2. Types of DILI (adapted from Björnsson ) 
inflammatory bowel disease cause also adverse drug reactions but the extended use of IBP 
makes them responsible of most of the adverse reactions with gastrointestinal drugs: 
hypergastrinemia, hypomagnesemia, tumors and, recently, enteric infections, pneumonia 
and osteoporosis (Maffei, 2007). There is a controversy about the probability of some of 
theses adverse drug reactions with IBPs. In the recent review by Thomson (2010) they failed 
to found risk of carcinoid tumors, cancer or nosocomial pneumoniae. There still controversy 
about the risk of osteoporosis with the long term use of IBPs.  
10. Strategies to diminish adverse drugs reactions 
The main strategies for reducing adverse drug reactions are: drug interaction calculators, 
renal insufficiency calculators, prescribing programs and collaboration between 
pharmacists, pharmacologists and clinical physicians.  
The world Health Organization defines pharmacovigilance as the science and activities 
related to the detection, assessment, understanding, and prevention of adverse affects or any 
other possible drug-related problem. The field has grown significantly in recent years as 
postapproval safety studies for new medication become increasingly required, 
encompassing retrospective analysis of heath-care claims databases, meta-analysis, patients 
registries, and prospective case-control studies.  
Recognition, reporting and careful characterization of these troubling, often unexpected 
ADRs are vital to future prevention of these event because detection of patterns and 
common features of ADRs can enhance our understanding of new mechanism and risk 
factors. The expansion of electronic database capabilities in hospital and primare-care 
setting offers the promise of better safety-based detection and monitoring systems that can 
detect ADRs earlier and prevent ADRs in the future. Hospital informatics systems linking to 
electronic medical records and including patient genotype with medication ordering and 
dispensing will reduce medication errors and inappropriate prescribing while improving 
www.intechopen.com
 
New Advances in the Basic and Clinical Gastroenterology 
 
520 
detection of ADRs. Also, the review of prescription by pharmacists can achieve a diminution 
in the appearance of adverse drug reactions.  
It´s also important to recognize people specially susceptible to ADRs: elderly, women, 
polipharmacy, renal insufficiency and presence of drug-drug interactions. In this special 
population we have to be careful with prescription of new drugs and its dosing.  
11. Conclusions 
Adverse drug reactions is a very frequent problem that affects specially the gastrointestinal 
tract, being GI bleeding the most common adverse drug reaction causing hospital 
admission. Patients predisposed to suffer ADRs are elderly, women, renal insufficiency, 
polipharmacy and drug-drug interactions. Drugs used for treat gastrointestinal disease are 
quite sure but can b e implicated in ADRs as IBPs, imunosupre4ssants used for autoimmune 
hepatitis or inflammatory bowel disease. Recognition of this problem is increasing in 
frequency and new drugs can be responsible for new ADRs. Collaboration between 
clinician, pharmacists and pharmacology specialists is needed. 
12. Appendix 1 
ICH Guideline on E2D post-approval drug safety defined an adverse drug reaction (ADR) 
and a serious adverse drug reactions (SADR) as follows:  
An adverse drug reaction, as established by regional regulations, guidance and practices, is 
concern noxious and unintended responses to a medicinal product. The phrase “responses 
to a medicinal product” means that a causal relationship between a medicinal product and 
an adverse event is at least a reasonable possibility (refer to the ICH E2A guideline). A 
reaction, in contrast to an event, is characterized by the fact that a causal relationship 
between the drug and the occurrence is suspected. For regulatory reporting purposes, if an 
event is spontaneously reported, even if the relationship is unknown or unstated, it meets 
the definition of an adverse drug reaction”. 
Serious adverse event /ADR. In accordance with ICH E2A guideline, a serious adverse 
event or reaction is any untoward medical occurrence that at any dose: 
 Results in death 
 is life-threatening (NOTE: The term “life-threatening” in the definition of “serious” 
refers to an event/reaction in which the patient was at risk of death at the time of the 
event/reaction; it does not refer to an event/reaction which hypothetically might have 
caused death if it were more severe), 
 is a congenital anomaly/birth defect, 
 is a medically important event or reaction. 
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious, such as important medical events that might not be 
immediately life-threatening or result in death or hospitalization but might jeopardize the 
patient or might require intervention to prevent one of the other outcomes listed in the 
definition above. Examples of such events are intensive treatment in a emergency room or at 
home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization or development of drug dependency or drug abuse.  
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13. Appendix 2 
Subject Information  
1. Temporal relationship of start of drug to ALT>2x ULN  Score 
Initial treatment 5–90 days; subsequent treatment course: 1–15 days  2 
Initial treatment <5 or >90 days; subsequent treatment course: >15 days  1 
From cessation of drug: <15 days, or <15 days after subsequent treatment 1 
Otherwise  0 
2. After drug cessation- difference between peak ALT and upper limits normal  
Decreases >50% within 8 days  3 
Decreases >50% within 30 days  2 
No information or decrease >50% after >30 days, or inconclusive 0 
Decrease <50% after 30 days or recurrent increase -2 
3. Risk factors  
No alcohol use 0 
Alcohol use 1 
Age <55 years  0 
Age >55 years  1 
4. Concomitant drug  
No concomitant drug administered 0 
Concomitant drug with suggestive or compatible time of onset  -1 
Concomitant known hepatotoxin with suggestive or compatible time of onset  -2 
Concomitant drug with positive rechallenge or validated diagnostic test  -3 
5. Nondrug causes: Six are primary: recent hepatitis A, B, or C, biliary obstruction, acute 
alcoholic hepatitis (AST > 2x ALT), recent hypotension 
Secondary group: Underlying other disease; possible CMV, EBV or HSV infection  
 
All primary and secondary causes reasonably ruled out:  2 
All 6 primary causes ruled out  1 
4 or 5 primary causes ruled out  0 
< 4 primary causes ruled out (max. negative score for items 4 and 5: –4) -2 
Nondrug cause highly probable  -3 
6. Previous information on hepatotoxicity of the drug in question  
Package insert or labelling mention  2 
Published case reports but not in label  1 
Reaction unknown  0 
7. Rechallenge  
Positive (ALT doubles with drug in question alone)  3 
Compatible (ALT doubles with same drugs as given before initial reaction) +1 1 
Negative (Increase in ALT but <2x ULN, same conditions as when  
reaction occurred)  
-2 
Not done, or indeterminate result  0 
Total (range of algebraic sum: –8 to +14)  
Score Interpretation: Highly probable >8; Probable 6–8;  
Possible 3–5; Unlikely 1–2; Excluded <0 
 
Reprinted from Toxicologic Pathology, 33, Lee, W.M. & Senior, J.R., Recognizing drug-induced liver 
injury: current problems, possible solutions, pp.155-64, copyright © 2005 by the Society of Toxicologic 
Pathology. Reprinted by Permission of SAGE Publications. 
Table 1. RUCAM Hepatocellular Injury Scale 
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Subject Information  
1. Temporal relationship of start of drug to ALP>2x ULN  Score 
Initial treatment 5–90 days; subsequent treatment course: 1–90 days  2 
Initial treatment <5 or >90 days; subsequent treatment course: >90 days  1 
From cessation of drug: <30 days, or <30 days after subsequent treatment 1 
Otherwise  0 
2. After drug cessation - difference between peak ALP or total bilirubin and ULN  
Decreases >50% within 180 days  2 
Decreases <50% within 180 days  1 
Persistence or increase or no information  0 
If drug is continued – inconclusive  0 
3. Risk factors  
No alcohol use 0 
Alcohol use 1 
Age <55 years  0 
Age >55 years  1 
4. Concomitant drug  
No concomitant drug administered 0 
Concomitant drug with suggestive or compatible time of onset  -1 
Concomitant known hepatotoxin with suggestive or compatible time of onset  -2 
Concomitant drug with positive rechallenge or validated diagnostic test  -3 
5. Nondrug causes: Six are primary: recent hepatitis A, B, or C, biliary obstruction, acute 
alcoholic hepatitis (AST > 2x ALT), recent hypotension 
Secondary group: Underlying other disease; possible CMV, EBV or HSV infection  
 
All primary and secondary causes reasonably ruled out:  2 
All 6 primary causes ruled out  1 
4 or 5 primary causes ruled out  0 
< 4 primary causes ruled out (max. negative score for items 4 and 5: –4) -2 
Nondrug cause highly probable  -3 
6. Previous information on hepatotoxicity of the drug in question  
Package insert or labelling mention  2 
Published case reports but not in label  1 
Reaction unknown  0 
7. Rechallenge  
Positive (ALT doubles with drug in question alone)  3 
Compatible (ALT doubles with same drugs as given before initial reaction) +1 1 
Negative (Increase in ALT but <2x ULN, same conditions as when  
reaction occurred)  
-2 
Not done, or indeterminate result  0 
Total (range of algebraic sum: –8 to +14)  
Score Interpretation: Highly probable >8; Probable 6–8;  
Possible 3–5; Unlikely 1–2; Excluded <0 
 
Reprinted from the Journal of Clinical Epidemiology, 46 (11), Danan, B. & Benichou, C., Causality 
assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international 
consensus meetings: application to drug-induced liver injuries, pp.1323-1330, copyright © 1993 by 
Pergamon Press Ltd. Reprinted with Permission from Elsevier. 
Table 2. RUCAM Cholestatic or Mixed Liver Injury Scale 
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Any one of the following: 
 More than or equal to fivefold elevation above the upper limit of normal (ULN) for alanine 
aminotransferase (ALT) 
 More than or equal to twofold elevation above the ULN for alkaline phosphatase (ALP) (particularly 
with accompanying elevations in concentrations of 5′-nucleotidase or γ-glutamyl transpeptidase in the 
absence of known bone pathology 
driving the rise in ALP level) 
 More than or equal to threefold elevation in ALT concentration and simultaneous elevation of 
bilirubin concentration exceeding 2× ULN 
Level of evidence: 2b (exploratory/retrospective cohort studies) 
Box 1. clinical chemistry criteria for drug-induced liver injury (DILI) (adapted from Aithal et 
al. 2011) 
 
 Pattern of liver injury is based on earliest identified liver chemistry elevations that qualify as DILI 
(Box 1) 
 Pattern of liver injury is defined using R value where R =(ALT/ULN)/(ALP/ULN). This will require 
estimation of alanine aminotransferase (ALT) (aspartate transaminase is used when ALT is 
unavailable) and alkaline phosphatase (ALP) from the same serum sample 
 ALT activity = patient’s ALT/upper limit of normal (ULN); ALP activity = patient’s ALP/ULN; R = 
ALT activity/ALP activity 
 Hepatocellular pattern of DILI = R ≥ 5 
 Mixed pattern of DILI = R > 2 and < 5 
 Cholestatic pattern of DILI = R ≤ 2 
 Histological summary should be recorded separately (if liver biopsy has been performed). However, 
the liver biopsy interpretation will generally not replace the R value for purposes of classification 
Level of evidence: 2b (retrospective cohort studies) 
Box 2. criteria for classifying the clinical pattern of drug induced liver injury (DILI) (adapted 
from Aithal et al. 2011) 
 
Category Severity Description 
1 Mild Elevated alanine aminotransferase/alkaline phosphatase 
(ALT/ALP) concentration reaching criteria for DILI* but 
bilirubin concentration <2× upper limit of normal (ULN) 
 
2 Moderate Elevated ALT/ALP concentration reaching criteria for DILI* 
and bilirubin concentration ≥2× ULN, or symptomatic hepatitis 
 
3 Severe Elevated ALT/ALP concentration reaching criteria for DILI*, 
bilirubin concentration ≥2× ULN, and one of the following: 
 International normalized ratio ≥1.5 
 Ascites73 and/or encephalopathy, disease duration <26 
weeks, and absence of underlying cirrhosis31 
 Other organ failure considered to be due to DILI 
4 Fatal or transplantation Death or transplantation due to DILI 
Box 3. DILI severity index (adapted from Aithal et al. 2011) 
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 The Roussel Uclaf Causality Assessment Method (RUCAM) scale should be used for causality 
assessment (Appendix 2) 
 If more than one drug is suspected to be causing DILI, the RUCAM scale should be applied to each 
drug separately. If such assessments are not practical (e.g., antituberculosis medications), all the drugs 
involved may be implicated as a single entity. 
 If more than one drug is rated “possible” or higher by RUCAM, evaluation should be sought by a 
specialist to rank the drugs by order of likelihood of causing DILI. This may be done on the basis of the 
signature pattern of DILI and a review of the literature. 
Level of evidence: 1b (validating cohort studies) 
Box 4. DILI causality assessment (adapted from Aithal et al. 2011) 
 
 Initial clinical episode met the criteria to qualify as acute DILI (Box 1) 
 Initial episode on causality assessment has been considered possible, probable, or highly probable 
DILI on the basis of Roussel Uclaf Causality Assessment Method scoring criteria (Appendix 2). 
Persistent DILI is defined as evidence of continued liver injury after withdrawal of the causative agent, 
beyond 3 months of follow-up for hepatocellular and mixed DILI, and beyond 6 months for cholestatic 
DILI 
 Chronic DILI is defined as evidence of continued liver injury after withdrawal of the causative agent 
beyond 12 months of follow-up, regardless of the classification of DILI 
 There is no new risk factor other than exposure to the suspect drug that would explain the 
persistence of liver injury, and other causes of chronic liver diseases have been excluded 
Level of evidence: 4 (prognostic cohort studies of modest quality) 
Box 5. Characteristics of persistent and chronic druginduced liver injury (DILI) (adapted 
from Aithal et al. 2011) 
 
 Evidence of chronic liver disease is established on the basis of validated methods such as clinical 
evidence of cirrhosis, histological evidence of chronic liver disease, and imaging in cases of vascular 
disorder and tumours, as appropriate 
 Evidence of drug intake for an appropriate duration preceding the appearance of symptoms, signs, 
or test results suggestive of chronic liver disease 
 Exclusion of other etiologies of chronic disease (outlined in Supplementary Appendix 2, table S3) 
Level of evidence: 1b (prospective/validating cohort studies with good follow-up) 
Box 6. characteristics of drug-associated chronic liver disease (adapted from Aithal et al. 
2011) 
 
 The score is ≥6 points on simplified diagnostic criteria for AIH (scores >6 points with the simplified 
criteria can be obtained if liver biopsy is performed. Hennes et al.()consider a probable diagnostic score 
to be ≥6) 
 Injury resolves on withdrawal of medication that triggered the AIH, with or without 
immunosuppressive therapy to induce remission 
 No relapse within a period of 1 year after withdrawal of all immunosuppressants. This criterion 
needs further confirmation and cannot be considered pathognomonic because it is quite variable 
depending on the cohorts analyzed 
Level of evidence: 2b (exploratory cohort study) 
Box 7. Characteristics of drug-induced autoimmune hepatitis (AIH) (adapted from Aithal et 
al. 2011) 
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